2025.01.17
Xi News | A Steady Stream, Steadfast Progress—Annual Conference Special Edition
As the years turn and new chapters unfold, Shanghai Xichang Bio’s Spring Annual Gala was held in grand style, amid widespread anticipation and the hopeful sentiment of “May the stream flow endlessly, and steady progress lead us far.” This event was not only a heartfelt reflection on the past year but also a warm occasion for all Xichang team members to gather together and look forward to the future.
2025.01.03
As biomedical innovation continues to flourish, a wide array of academic conferences and exchange events have become platforms for intellectual dialogue, technological showcase, and collaborative expansion within the industry.
2024.10.22
Xi News | A Team-Building Journey by the Shanyan Lake — Special Feature on Corporate Team Building
In this fast-paced work environment, we’re always seeking moments that allow our hearts to rest and bring our teams closer together. On October 18, Shanghai Xichang Bio, under the rallying cry “United in Purpose, Integrated for Mutual Success,” led a group of passionate, dream‑driven colleagues on a team‑building retreat to Dianshan Lake, weaving together an unforgettable chapter of shared memories.
2025.03.27
“Targeting” the Lead: The Next PD‑1? Exploring the SOX17 Target
The immune system serves as the body’s primary defense against tumors; however, cancer cells often employ “immune evasion” mechanisms to disguise themselves and evade recognition and attack by immune cells. Although immune checkpoint therapies, exemplified by PD‑1/PD‑L1 inhibitors, have achieved remarkable progress in advanced cancers, their efficacy remains limited for early-stage tumors, such as colorectal cancer.
2025.01.09
Xi News | Synthetic Fab HuCAL GOLD Library Screening Helps Fizezumab Advance Toward Market Launch
On January 8, 2025, the marketing application for Fasenra, a CD38‑targeting antibody injection developed by Tianjing Biologics, was accepted by the NMPA. This landmark advancement undoubtedly heralds new hope for second‑line treatment of patients with multiple myeloma.
2025.01.05
The commercial development of antibody therapies is a global endeavor, involving tens of thousands of biopharmaceutical companies and supporting service providers. To date, their collective efforts have brought more than 200 antibody therapies to market, with nearly 1,400 additional product candidates in the pipeline currently undergoing clinical evaluation for the treatment of a wide range of diseases.
2025.01.02
STEAP1 belongs to the prostate-specific transmembrane epithelial antigen (STEAP) family, which, in addition to STEAP1, includes STEAP2, STEAP3, and STEAP4. These proteins are involved in numerous biological processes, including apoptosis and cell proliferation, oxidative stress, and the transport of molecules across cellular membranes.
03
2025
/
01
05
2025
/
01
02
2025
/
01
Subscription Information
Subscribe to receive updates from Xichang News.
Shanghai Constream biotechnology Co., Ltd
Phone:021-59255902
Address: Building 2, Floors 2–3, Lane 10688, Beiqing Road, Qingpu District, Shanghai
WeChat Official Account
Copyright © 2026 Shanghai Constream biotechnology Co., Ltd.